Streetlab VR for AMD

Recruiting in Palo Alto (17 mi)

Overseen byEleonora Lad, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Duke University

No Placebo Group

Trial Summary

What is the purpose of this trial?The goal is to conduct a cross-sectional, single timepoint study on older adults with early and intermediate AMD, and with subretinal drusenoid deposits (SDD), and those in normal health, establishing an association between dark adaptation and reading performance under dim illumination, both which depend on rod photoreceptors.

Eligibility Criteria

This trial is for adults over 50 with early to intermediate dry age-related macular degeneration or geographic atrophy, and healthy individuals as controls. Participants must be able to consent and have no conditions like dense cataracts, severe myopia, nystagmus, glaucoma requiring treatment, or any condition that could affect the study's procedures.

Inclusion Criteria

I am able and willing to give my consent.

I am 50 years old or older.

I have early or intermediate dry age-related macular degeneration or geographic atrophy, or my macula is healthy.

Exclusion Criteria

I am under 50 years old.

I have dense cataracts in my eye(s) affecting my vision tests.

High myopia -8 Diopters or more severe

+7 more

Participant Groups

The study examines how well older adults with different stages of AMD can adapt to darkness and read in dim light using a virtual reality system called Streetlab VR. It aims to link dark adaptation (which relies on rod photoreceptors) with reading performance under low illumination.

4Treatment groups

Experimental Treatment

Group I: Intermediate AMDExperimental Treatment1 Intervention

Study patients who have a diagnosis of Intermediate AMD

Group II: Geographic AtrophyExperimental Treatment1 Intervention

Study patients who have a diagnosis of Geographic Atrophy

Group III: Early AMDExperimental Treatment1 Intervention

Study patients who have a diagnosis of early AMD

Group IV: AMD ControlsExperimental Treatment1 Intervention

Study patients who have healthy eyes